GlassScriptPhysician profile
Pius E Ehiane
NPI 1962801951
$4,811.71
in general payments reported to CMS, 2019-2025
20 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what 85% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $723 · 2022: $957 · 2023: $848 · 2024: $1,012 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,131.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $921.91 | 2021-2025 | Caplyta |
| Alkermes, INC. | $789.58 | 2021-2025 | Aristada, Lybalvi |
| Abbvie INC. | $753.32 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $454.56 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $434.01 | 2022-2025 | Invega Sustenna, Spravato, Invega |
| E.R. Squibb & Sons, L.L.C. | $309.27 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $174.95 | 2021-2025 | Rexulti |
| Bausch Health US, LLC | $149.79 | 2022-2025 | Aplenzin |
| Corium, LLC | $139.31 | 2022-2024 | Azstarys |
| Axsome Therapeutics, INC. | $131.59 | 2022-2023 | Auvelity |
| Avanir Pharmaceuticals, INC. | $129.32 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $115.14 | 2024 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $84.24 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $70.20 | 2021-2024 | Qelbree, Qelbree |
| Eisai INC. | $33.87 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $30.97 | 2023 | Methylphenidate Hydrochloride |
| Takeda Pharmaceuticals U.S.A., INC. | $28.70 | 2022 | |
| Tempus Ai, INC | $26.34 | 2024 | |
| Neurocrine Biosciences, INC. | $18.37 | 2025 | |
| Idorsia Pharmaceuticals US INC | $16.27 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pius Ehiane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.